VitaLonga

Clinical trial · Research · 16 Nov 2026

In 28 women with early breast cancer, adding fluzoparib to chemotherapy left a low rate of minimal residual tumor

Source: Breast Cancer Research and Treatment

What the research found

A single-arm phase 2 trial was published online on 16 November 2026. This was a trial in women aged 18 to 70 with newly diagnosed hormone-receptor-positive, HER2-negative early breast cancer that was homologous-recombination deficient, germline BRCA-mutated, or both. Twenty-eight women enrolled between March 2023 and October 2025. They received fluzoparib with docetaxel for four cycles, then epirubicin plus cyclophosphamide for four cycles. The abstract does not give a mean age. Four of 28 (14.3 percent, 95 percent CI 4.0 to 32.7) reached residual cancer burden grade 0 or I. Two of 28 (7.1 percent, 95 percent CI 0.9 to 23.5) had a total pathological complete response. Six of 28 (21.4 percent, 95 percent CI 8.3 to 41.0) had a breast pathological complete response. The objective response rate was 82.1 percent. Grade 3 to 4 treatment-related side effects occurred in four women (14.3 percent). Nobody stopped, reduced a dose, delayed a cycle, or died from the regimen. There was no comparison group. The authors report that the residual-burden rate was not improved. Registry NCT07162051. This is not a dosing guide. DOI 10.1007/s10549-026-08126-w. Not medical advice.

Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.

Read the original at Breast Cancer Research and Treatment

More research news